Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 3Lung Neoplasms 2Leukemia 2Urogenital Neoplasms 1Solid Tumors 1Small Cell Lung Carcinoma 1Recurrence 1Recovery 1Ovarian Neoplasms 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Keratosis, Actinic 1Genital Neoplasms, Male 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

aldesleukin 42Sunitinib 39Cyclophosphamide 30Nivolumab 27Everolimus 27pembrolizumab 26Interferon-alpha 25Bevacizumab 22Sorafenib 21Interleukin-2 20fludarabine phosphate 19Filgrastim 18Ipilimumab 17Radiotherapy 16Axitinib 16Peripheral Blood Stem Cell Transplantation 15Gemcitabine 15cabozantinib 14fludarabine 11Radiosurgery 11Doxorubicin 11Carboplatin 11temsirolimus 10Etoposide 9Chemotherapy, Adjuvant 9sargramostim 8belzutifan 8atezolizumab 8Fluorouracil 8pazopanib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Kidney Neoplasms × Powders × Clear all
NCT04260360 2020-08-04

Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma

NanOlogy, LLC

Phase 1 Withdrawn
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡